返回 
加入收藏
补肺化瘀汤联合化疗治疗非小细胞肺癌的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 补肺化瘀汤联合化疗治疗非小细胞肺癌的临床观察 |
| TITLE： | |
| 摘要： | 目的：观察补肺化瘀汤联合化疗治疗非小细胞肺癌（NSCLC）的临床疗效、安全性及其对血管内皮生长因子（VEGF）及免疫功能的影响。方法：选取2013年10月－2015年6月在我院接受治疗的NSCLC患者120例作为研究对象，按随机数字表法分为观察组和对照组，各60例。对照组患者给予GP（吉西他滨+顺铂）方案化疗，观察组患者在对照组基础上加用补肺化瘀汤，每日1剂，水煎取汁400 mL，分早晚2次温服。比较两组患者临床疗效及治疗前后血清VEGF-A、VEGF-B、VEGF-C和免疫指标（CD3+、CD4+、CD8+、CD4+/CD8+）水平，并记录毒副反应发生情况。结果：观察组患者的临床有效率、疾病控制率分别为58.33％、85.00％，显著高于对照组的40.00％、68.33％，差异均有统计学意义（P＜0.05）。治疗前，两组患者VEGF及免疫指标水平比较，差异均无统计学意义（P＞0.05）。治疗后，两组患者血清VEGF水平均显著降低，且观察组显著低于对照组，差异均有统计学意义（P＜0.05）；两组患者CD4+、CD4+/CD8+水平均显著降低，CD8+显著升高，且观察组患者CD4+、CD4+/CD8+均显著高于对照组，CD8+显著低于对照组，差异均有统计学意义（P＜0.05）；对照组患者CD3+显著降低，且显著低于观察组，差异均有统计学意义（P＜0.05）。观察组患者白细胞下降、血小板减少、血红蛋白下降、转氨酶升高、胆红素升高、消化道反应的发生率均显著低于对照组，差异有统计学意义（P＜0.05）。结论：补肺化瘀汤联合化疗治疗NSCLC疗效显著，能有效抑制患者VEGF水平，改善免疫功能，减轻毒副反应。 |
| ABSTRACT： | OBJECTIVE： To observe clinical efficacy and safety of Bufeihuayu decoction combined with chemotherapy in the treatment of non-small cell lung cancer （NSCLC） and its effects on vascular endothelial growth factor （VEGF） and immune function. METHODS： A total of 120 NSCLC patients in our hospital during Oct. 2013 to Jun. 2015 selected as research object were divided into observation group and control group according to random number table， with 60 cases in each group. Control group was given GP （gemcitabine combined with cisplatin） chemotherapy. Observation group was additionally given Bufei huayu decoction， one dose a day， decocted to 400 mL， morning and night， on the basis of control group. Clinical efficacies of 2 groups were compared， and VEGF-A， VEGF-B， VEGF-C and immune indexes （CD3+， CD4+， CD8+， CD4+/CD8+） levels were compared before and after treatment. The occurrence of toxic reaction was recorded. RESULTS： Response rate and disease control rate of observation group were 58.33％ and 85.00％， significantly higher than 40.00％ and 68.33％ of control group， with statistical significance （P＜0.05）. Before treatment， there was no statistical significance in levels of VEGF or immune indexes between 2 groups （P＞0.05）. After treatment， VEGF of 2 groups were decreased significantly， and observation group was significantly lower than the control group， with statistical significance （P＜0.05）； CD4+ and CD4+/CD8+ of 2 groups were decreased significantly， while CD8+ was increased significantly， with statistical significance （P＜0.05）； CD4+ and CD4+/CD8+ of observation group were significantly higher than those of control group， while CD8+ was decreased significantly； CD3+ of control group was decreased significantly and lower than observation group， with statistical significance （P＜0.05）. The incidence of leucopenia， thrombocytopenia， decrease of hemoglobin， elevation of transaminase， increase of bilirubin and digestive tract reaction in observation group was significantly lower than control group， with statistical significance （P＜0.05）. CONCLUSIONS： Bufei huayu decoction combined with chemotherapy shows significant therapeutic efficacy for NSCLC， can effectively inhibit VEGF， improve immune function and relieve toxic reaction. |
| 期刊： | 2017年第28卷第35期 |
| 作者： | 冯原，周继红，陈斯宁，江颖，周颖 |
| AUTHORS： | FENG Yuan，ZHOU Jihong，CHEN Sining，JIANG Ying，ZHOU Ying |
| 关键字： | 补肺化瘀汤；非小细胞肺癌；血管内皮因子；免疫功能 |
| KEYWORDS： | Bufei huayu decoction； Non-small-cell lung cancer； Vascular endothelial growth factor； Immune function |
| 阅读数： | 255 次 |
| 本月下载数： | 2 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
